Exploring barriers to commercial peanut oral immunotherapy treatment during COVID-19

Leef, Chelsea; Horton, Codi; Lee, Tricia; Lee, Gerald; Tison, Katherine; Vickery, Brian P.

doi:10.1016/j.jaip.2021.08.044

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first prospective study to evaluate factors influencing real‐world uptake included 237 PA patients where 90.7% declined therapy, with the two most common reasons being “concern over adverse effects,” and “concern over the degree of commitment.” The most common reason to pursue POIT was “protection against accidental ingestion.” Poor baseline QOL, especially in preteen ages and with caregivers, was the strongest predictor of pursuing OIT 23 . Another study from the authors' own institution similarly noted a high proportion declining therapy, citing time burden associated with therapy and the daily lifestyle modifications required to dose safely 24 …”

Section: Peanut Oral Immunotherapymentioning

confidence: 93%

See 1 more Smart Citation

Current and future treatments for peanut allergy

Lee

Edwards-Salmon

Vickery

2022

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Peanut allergy (PA) is a common, burdensome childhood disease that in most patients continues into adulthood and has historically been untreatable. However, peanut oral immunotherapy (POIT) is increasingly being incorporated into allergy practices, using both the first FDA‐approved product, PTAH (previously AR101; Palforzia™, Aimmune Therapeutics), as well as store‐bought peanut products. POIT in preschoolers continues to gain more acceptance as evidence accrues that it is a safe and feasible approach that may have distinct advantages. There are many new therapeutic interventions currently under study with a variety of different approaches and potential mechanisms. With respect to other forms of immunotherapy, none are currently approved, but the epicutaneous approach is the most well‐studied and others are being actively investigated, including sublingual, subcutaneous, and intralymphatic. Biologics are gaining evidence both as adjunctive treatments to POIT and as monotherapy. Omalizumab is the most widely studied biologic for PA but others also have potential. Looking ahead to a future therapeutic landscape of choice, allergists will need to understand each patient's goal of treatment through shared decision‐making and fully evaluate the risks, benefits, and alternatives of each new therapy.

show abstract

Section: Peanut Oral Immunotherapymentioning

confidence: 93%

“…23 Another study from the authors' own institution similarly noted a high proportion declining therapy, citing time burden associated with therapy and the daily lifestyle modifications required to dose safely. 24…”

Section: Ptahmentioning

confidence: 99%